Arcturus Therapeutics Holdings Inc. (ARCT) Earnings Call Transcript & Summary

November 5, 2026

NASDAQ US Health Care Biotechnology earnings 51 min

Earnings Call Speaker Segments

Neda Safarzadeh

executive
#1

Thanks, operator. Good afternoon, everyone, and welcome to the Arcturus Therapeutics quarterly financial update and pipeline progress call. Joe Payne, our President and CEO, and Dennis Mulroy, our Chief Financial Officer, will lead today's call. Dr. Pad Chivukula, our CSO and COO, along with Dr. Alan Cohen, our Chief Medical Officer, will join them for the Q&A session. Before we get started, I'd like to remind everyone that statements made on this call about matters that aren't historical facts are forward-looking statements under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements don't guarantee performance; they carry known and unknown risks, uncertainties, and assumptions that could cause actual results, performance, and achievements to differ materially from what this statement expresses or implies. Please refer to the forward-looking statement disclaimer in the company's press release issued earlier today, and also to the risk factor section in our most recent Form 10-K and in later filings with the SEC. Also, any forward-looking statements reflect our views only as of the date such statements are made. Arcturus specifically disclaims any obligation to update such statements. With that, I'll now hand the call over to Joe.

Joe Payne

executive
#2

Thank you, Neda. Good afternoon, everyone, and thanks for being with us today. For Arcturus, the third quarter was a significant stretch, as we kept moving our main clinical programs forward, launched our next-generation LUNAR 2.0 delivery platform, and grew our pipeline of mRNA therapeutics. I want to start with the liver therapeutics franchise, where we think we're entering an exciting new stage of development. In September, we shared encouraging phase II results for ARCT-810 in patients who have ornithine transcarbamylase, or OTC, deficiency. At the 0.3 and 0.5 milligram per kilogram dose levels, ARCT-810 showed meaningful biomarker activity — it reduced and/or maintained first morning fasting ammonia within the normal range, including when protein intake was increased, and it lowered glutamine levels in every participant, with the 0.5 milligram per kilogram dose reaching mean glutamine concentrations within the normal range during treatment, and the drug was generally safe and well tolerated. These findings give us important clinical validation of our mRNA approach to liver therapeutics and helped shape our next-generation OTC program, ARCT-2601. ARCT-2601 matters a great deal to Arcturus because it is the first mRNA therapeutic candidate to use our new LUNAR 2.0 delivery technology. Non-human primate models have consistently shown strong translational predictivity for lipid nanoparticle-formulated RNA therapeutics. That's well documented; in non-human primates, we're able to measure human ornithine transcarbamylase expression. In this non-human primate model, we showed a 38-fold improvement in potency with LUNAR 2.0 versus the original LUNAR formulation used in ARCT-810; we believe this substantial gain in delivery efficiency could allow lower and less frequent dosing and potentially widen the range of diseases we can target with our mRNA therapeutics. We shared the LUNAR 2.0 data with the FDA. After favorable FDA feedback and clarity on the regulatory pathway from our Type C meeting in June, we now plan to begin phase II dosing of ARCT-2601 next quarter. The amended protocol will evaluate patients with OTC deficiency ages 12 and older, and we expect top-line data in the second half of 2027. Safe and effective mRNA delivery sits at the core of our thesis. We work in RNA therapeutics, where delivery is everything, so you can see why we look forward to this first potential clinical top-line data for ARCT-2601, since this is the first chance to confirm how the 38-fold improvement we saw in non-human primates translates into patients. Beyond OTC deficiency, LUNAR 2.0 is letting us expand our liver therapeutics pipeline into additional genetic diseases, including phenylketonuria, or PKU, and gout. For PKU, we're developing an investigational LUNAR 2.0-formulated mRNA therapy designed to enable the liver to produce functional PAH; that's the enzyme patients with PKU are deficient in. Our goal is to restore PAH activity, improve phenylalanine metabolism, and ultimately address the underlying cause of the disease; we currently plan to submit an IND for this program in the second half of 2027. Moving on to respiratory now. With ARCT-032 in CF, we're still making headway. Enrollment for cohort four of the phase II trial has picked up speed now that we've opened more clinical sites in Israel and Turkey. We're expecting that enrollment to wrap up by year-end, and full cohort four data is slated for presentation in the second quarter of 2027. In cohort four, we're looking at 10 milligrams of ARCT-032 given by inhalation over 12 weeks in up to 20 adults with cystic fibrosis, mostly class I CF subjects. We're also glad to have Thermo Fisher Scientific's ongoing backing for the ARCT-032 program. Per our collaboration, a choice to move ARCT-032 into phase III would set off substantial contributions from Thermo Fisher, and we'd expect that call when top-line data becomes available, ahead of the planned full phase II data presentation. Given the steady flow of patients enrolling in Turkey and Israel, data from those patients could be included to help inform that decision. Thermo Fisher gets regular updates as set out in our agreement, and under that agreement, the call on advancing ARCT-032 to phase III stays with Arcturus. During the quarter, we kept building out our wider technology capabilities and AI infrastructure as well. We closed the acquisition of myNEO, which brings in AI-driven capabilities for antigen design, mRNA optimization, and target identification. We think combining those capabilities with our existing mRNA design and delivery know-how could speed up pipeline development and open up further strategic opportunities, oncology included, given that myNEO has seven years of experience expertly designing neoantigens. Over on the vaccine side, KOSTAIVE, our self-amplifying mRNA COVID shot, is still being commercialized in Japan by our partner Meiji for the 2026 to 2027 season. We also finished transferring the marketing authorization holder rights for KOSTAIVE in the European Union and the U.K. alike, from CSL Seqirus over to Arcturus. Those transfers matter as an important step while we work toward carrying out commercial objectives for KOSTAIVE in 2027. We also recently had the results of our phase I study of our self-amplifying mRNA pandemic influenza vaccine published in Nature Communications. That study showed immunological benefits against standard of care, a favorable safety profile, and the potential for a single-dose pandemic response. All told, we think these developments across our vaccine enterprise show how broad our mRNA platform is and how Arcturus has evolved; we now have key programs moving forward in respiratory and liver therapeutics, a next-generation delivery technology in LUNAR 2.0, a growing pipeline in genetic diseases, extra AI-enabled discovery capabilities via myNEO, and a commercial vaccine platform headed by KOSTAIVE. Looking forward, several important milestones are coming up. We expect to finish enrollment in the ARCT-032 phase II study by year-end, present the full phase II CF data in the second quarter of 2027, start phase II dosing of ARCT-2601 in the first quarter of 2027, and report top-line ARCT-2601 data in the second half of 2027. We're still concentrating on executing with discipline and moving forward the programs where we think our technology can make a real difference for patients and create lasting value for shareholders. With that said, I'll hand things over to Dennis so he can walk through our financial results for the third quarter.

Dennis Mulroy

executive
#3

Thanks, Joe, and good afternoon, everyone. In the press release we issued earlier today, you'll find financial statements covering both the three and nine months ended September 30, 2026, along with a summary and analysis of how performance compares year over year. For additional detail on our financial performance, please also refer to our Form 10-Q. As of September 30, 2026, cash and cash equivalents stood at $184.8 million, versus $230.9 million on December 31, 2025 — a decrease of $46.1 million across the first nine months of 2026. The drop largely came from cash used for ongoing clinical development work, including continued progress on the company's cystic fibrosis and OTC deficiency programs, partially offset by a $12 million payment from CSL Seqirus under the termination and settlement agreement. For the three and nine months ended September 30, 2026, revenue was $18.3 million and $23.3 million, versus $17.2 million and $74.8 million in the corresponding periods a year earlier. For the three-month period, the main driver of the increase was recognition of the $12 million termination payment along with the remaining deferred revenue tied to ending the CSL Seqirus collaboration, through which the company took back strategic control of KOSTAIVE and its wider vaccine portfolios, partially offset by reduced grant revenue. Turning to the nine-month figure, the decline stemmed primarily from revenue recognized under the CSL Seqirus collaboration before it was terminated, together with lower BARDA grant revenue. R&D expenses came in at $17 million and $56 million for the three and nine months ended September 30, 2026, versus $23.3 million and $87.7 million in the same periods of 2025. The main reason for those declines was less work in clinical and manufacturing, especially in the LUNAR-COVID and BARDA programs, along with reduced personnel and facility costs, as the company keeps pushing its top-priority programs forward and stays disciplined about how it allocates capital. G&A expenses came to $10.5 million and $30.9 million for the three and nine months ended September 30, 2026, versus $10.4 million and $32.1 million in the same period a year earlier. On the whole, G&A held roughly flat for the quarter, while the year-to-date drop was mostly due to lower payroll and benefit costs and reduced share-based compensation expense, both stemming from a smaller headcount and partly offset by higher legal and professional fees. For the three and nine months ended September 30, 2026, our net loss came to $7.4 million and $58.2 million, respectively, which works out to a net loss per share of $0.26 and $2.05. That compares with a net loss of $13.4 million and $36.7 million for the three and nine months ended September 30, 2025, or $0.49 and $1.35 per share. Disciplined investment in the programs and technologies we believe will deliver the greatest long-term value remains our priority. We're excited about the recent acquisition of myNEO and about collaborating with their talented team as we fold their strong expertise into our future strategic relationships. Our balance sheet remains solid, and we have a cash runway extending beyond 2 years through the end of 2028, which gives the company the ability to hit key clinical and regulatory milestones across our mRNA therapeutic pipeline. With that, I'll hand the call back over to Joe.

Joe Payne

executive
#4

Thanks, Dennis. As you can hear, Arcturus is heading into a significant stretch, with several data milestones across our pipeline that could create value, along with a solid balance sheet and a disciplined approach to allocating capital. With that, operator, we're ready for questions.

Lili Nsongo

analyst
#5

Hello, and thanks for the update. I have a few questions, perhaps, about the cystic fibrosis program. Could you remind us of the number of patients dosed so far? I believe you said dosing should be finished by year-end 2026, and my recollection is that target enrollment was 20 patients. Regarding the go/no-go decision and top-line data, should we expect that at least 12 weeks following completion of the cohort, or might you present a smaller dataset first?

Joe Payne

executive
#6

Thank you, Lili, for those questions. Well, to begin with, the cohort size has not changed. It is roughly 20 people, up to 20 subjects, mainly class 1 CF individuals. Most of these have been coming from Israel and Turkey, and we have highlighted that. We have not disclosed the exact number recruited so far, but we have shared our confidence about completing that enrollment by year-end. As for the data presentation, the intent is a full dataset covering all approximately 20 of these subjects once enrollment is complete, the entire fourth cohort. So it will be a fulsome dataset, and that presentation we have guided now in Q2.

Lili Nsongo

analyst
#7

And only to make sure, so that will be a complete dataset too for the top-line data that guides the go/no-go call?

Joe Payne

executive
#8

Yes, precisely. The go/no-go call is expected once top-line data becomes available, and that should be ready before, in all likelihood, the full phase II data presentation we have planned for Q2.

Lili Nsongo

analyst
#9

Okay. Thank you.

Joe Payne

executive
#10

Thank you.

Evan Wang

analyst
#11

Hi everyone, Evan Wang here, standing in for Seamus Fernandez. So, just a few things from my side, I guess. First, one clarification about cystic fibrosis. So, when you bring up the planned presentation in 2Q, is that referring to a medical meeting, or do you mean a separate top-line readout? Second, regarding the OTC program in 2601, I'm wondering if you could offer any more detail on the design there, the evaluation of one or two doses, dose levels. Now that you've sort of guided to top-line data in second half, is that like a full dataset of somewhere between three and six patients? Curious whether there's anything you can share on that. Thank you.

Joe Payne

executive
#12

Sure. We haven't shared exactly how the Q2 presentation will be done, though it will probably happen at a conference, so keep an eye out for details. Regarding the 2601 dataset, yes—we want to be sure we have enough data to give us some early confidence in the 2601 proof of concept, so that we can share it together with the ARCT-810 data at the EOP2 meeting once that first dataset has been gathered. Now, Alan, would you like to add anything?

Alan Cohen

executive
#13

Yeah, Joe, I'm on the call. Thank you.

Joe Payne

executive
#14

All right.

Alan Cohen

executive
#15

To make sure we're on the same page and to reinforce what Joe just mentioned, regarding the 2601 dataset, we intend to enroll up to six subjects, and the goal is to have the complete dataset available together with the 810 data, so that we can present all of that data at an EOP2 meeting with the FDA. Using that data and what we think we've seen and accomplished, we'd rely on it to build and design a phase III program going forward.

Evan Wang

analyst
#16

Could I just ask one more question about cystic fibrosis, simply to get clarity on when the top-line press release data might come out.

Joe Payne

executive
#17

On top-line data, everything we've said is that it will be before — for CF, top-line data will be ready ahead of the full data presentation. Or did you mean the OTC data?

Evan Wang

analyst
#18

What I was referring to was cystic fibrosis.

Joe Payne

executive
#19

Right, the CF data, yes. Top-line results for the CF data are going to come out ahead of the full data presentation.

Evan Wang

analyst
#20

All right, thanks.

Analyst

analyst
#21

Oh, hello there. Appreciate you taking our questions. Quan Ang here for Yanan; regarding the CF program, since this is an open-label study, I'd assume the company is monitoring data in real time. Could you tell us whether you're still confident that 12 weeks would be enough to capture a consistent benefit across patients?

Joe Payne

executive
#22

Yes, we are certainly confident that 12 weeks is sufficient. As for restricting real-time access to the data, Alan, perhaps you could address both of those questions.

Alan Cohen

executive
#23

To reinforce what Joe said, we feel strongly that if a measurable clinical signal is going to emerge, 12 weeks ought to be enough, using clinically relevant endpoints like shifts in percent predicted FEV1 measured by spirometry and changes in MBW through lung clearance index, along with the two quality-of-life measures and HRCT changes across those 12 weeks. On the open-label point, we've been dedicating considerable effort to ensuring that only medical personnel, myself included, currently can see that open-label data. Access is mainly for safety monitoring rather than efficacy monitoring at this stage. We don't want that data to accidentally shape how we move forward with the study or how we gather the rest of the remaining dataset. At present — and I can report that patients have completed all 12 weeks on the current regimen of 10 milligrams once daily by inhalation — we're confident, based on what we've collected so far, that we'll be able to keep enrolling and gather that data in full, ideally before this calendar year ends.

Analyst

analyst
#24

Understood. That's really useful. A quick question about OTCD. From what you've seen in your FDA interactions regarding ARCT-810 up to now, do you believe there's clarity around a possible pivotal endpoint for the OTCD program more broadly? And does the preclinical data for ARCT-2601 carry any implications for how likely success is on that endpoint? Thank you.

Joe Payne

executive
#25

Yes, on the likelihood of success, clearly we're quite optimistic given the 38-fold improvement observed in primates, and that this will carry over positively into human data. But when it comes to endpoint clarity for ARCT-2601, perhaps you could elaborate, Alan.

Alan Cohen

executive
#26

Absolutely. If we take history as a reasonable guide — and we think it is — since the drugs approved today for OTC deficiency work by stabilizing serum ammonia and bringing it down, we know for sure that the biomarkers where we've seen shifts, which we consider clinically meaningful and important — both the decreases in glutamine and the decreases in ammonia — will without question be the central area where the FDA will want to see ongoing improvement and change over time. As you may remember, we also had patients who loosened their dietary protein intake, so we could observe that even while those patients were consuming more protein, they still achieved reductions and stabilization in glutamine and ammonia levels across the remainder of the dataset we've gathered so far. Those are the key areas of focus that we expect the agency will want to keep seeing evidence of clinical efficacy in, and they will without question be relevant primary and secondary endpoints for a phase III study like this.

Analyst

analyst
#27

Understood. I appreciate all the detail.

Myles Minter

analyst
#28

Hi, everyone. Thanks for taking my questions. My first is on 2601. I believe you've said before that patients enrolled in that cohort would have elevated ammonia at baseline, and I know patients treated with 810 earlier had ammonia levels that were relatively controlled at baseline. I'm just curious how that different patient population could shift your expectations for the data there. Second, Joe, you brought up oncology. I'd be remiss if I didn't ask: are you going to become a personalized neoantigen vaccine company? Thank you.

Joe Payne

executive
#29

Sure. Let me take the cancer question first, and then, Alan, you can address the elevated ammonia question regarding 2601. Arcturus is focused on executing our mRNA therapeutics pipeline. I want that to be clear. That said, we do possess technology and capabilities that can enable key players in oncology; with the recent acquisition of myNEO, we now have neoantigen design capabilities, and we clearly have a differentiated saRNA platform that engages T cells better, for instance, along with proven mRNA delivery and manufacturing; so for these reasons, of course, we're always open to enabling key players in oncology, but I also want my message to be equally clear that this year we're focused on executing our mRNA therapeutics pipeline. Alan, over to you.

Alan Cohen

executive
#30

Sure — happy to go deeper on your question about ammonia and glutamine levels across the study's patient populations. Even when patients do everything they can within their current care — substantially reducing protein intake, with most if not all of them on ammonia binding agents like Ravicti — despite those efforts, it's quite common for patients to be walking around with ammonia levels up near the top of what's considered the normal range, and as a result, they don't feel well. They deal with mental cloudiness and fog, GI upset, headaches, and so on. In the ARCT-2601 trial, our aim is to focus on patients we can access for the study whose ammonia and glutamine readings sit toward the upper range, which should make the changes we measure as clear as possible. We understand that at this point, demonstrating ongoing decreases and steadiness in those values—especially as we move into younger age brackets over time—would be meaningful; for stable adults, the difficulty is really about quality of life, day-to-day functioning, and being able to consume ordinary amounts of protein throughout the day. When it comes to children, what we sometimes see are those sudden surges with extremely elevated ammonia, and that ammonia passes through the blood-brain barrier, producing neurological damage that cannot be reversed. As we move downward through the age groups—from stable adults to adolescents and then to the youngest children—the types of signals we will be monitoring, along with how steady those changes remain over time, will grow more and more important. That is right. We will keep enrolling patients whose baseline levels, in spite of their best efforts, sit toward the higher end, which allows us to determine stability as well as changes and reductions in both glutamine and ammonia across the study period.

Myles Minter

analyst
#31

Thanks, guys.

Joe Payne

executive
#32

Thank you.

Whitney Ijem

analyst
#33

Hi, everyone. Appreciate you taking my question, and congratulations on the progress. Apologies for returning to this topic, but I did just want to attempt to clarify the CF data timing a third time. Just to confirm I got it right—

Joe Payne

executive
#34

Yeah

Whitney Ijem

analyst
#35

So now you're saying the go/no-go call will rest on the top-line data that's going to be in hand before 2Q? Before, that go/no decision was anticipated around year-end — so does that mean you expect top-line data in this year's fourth quarter? I just want to be really clear on that.

Joe Payne

executive
#36

Yeah. No, we've laid out very clear goalposts here: enrollment completes at year-end, and guidance for a full data presentation points to Q2. As for when the decision is expected, a couple of things have to be recognized. One is top-line data being available — and what does that cover? We've already said that top-line data, by definition, comes before our planned full data presentation. But the ongoing bolus of patients we're enrolling in Turkey and Israel — data generated from those patients may be included to inform that decision; it doesn't have to be, but it may be, and we just want to keep that above ground and open for everybody. On the timing of that data, we haven't guided the specifics, but once we have it, it'll give us the opportunity to share and to provide that decision.

Whitney Ijem

analyst
#37

All right, understood. It's possible the go/no-go call won't be made until after year-end. Is that simply because it hinges on when the data presentation occurs?

Joe Payne

executive
#38

Yes. We haven't given any indication on that. Today the sole fresh guidance we've put out concerns the data presentation. During September, when the team attended the bank conference season, we picked up feedback — we heard that people wanted guidance on the timing of the data presentation. That is what we've added. Right.

Whitney Ijem

analyst
#39

All right, that's clear. I just wanted to make sure I understood that point. Okay. Then my second question concerns the plans for KOSTAIVE in the U.S. and Europe. I believe there was some language about moving toward commercialization next year. Do you intend to handle that yourselves, or will you look for a partner? Thanks.

Joe Payne

executive
#40

Yes. Now that the market authorization holders have moved from CSL Seqirus over to Arcturus, that gives us a chance to take part in additional commercial activities outside Japan in 2027. As for the U.S., our position has been consistent: we would seek a partner for the U.S. region, but we have also said that, given the separation agreement with CSL, we now have the opportunity to explore commercial activities next year in Europe and the U.K. So we now have the chance to do that. That is correct.

Whitney Ijem

analyst
#41

Got it. Thanks.

Joe Payne

executive
#42

Thanks, Whitney.

Adam Walsh

analyst
#43

Hello there, good afternoon, and thank you for taking my questions. My first one concerns the CF. Should a go decision be made there, what would the chief obstacles be to launching a phase III, and is 2027 a realistic timeframe for that?

Joe Payne

executive
#44

Yeah. Alan is able to speak to that, but yeah, go ahead, Alan.

Alan Cohen

executive
#45

Right. So the aim — and Joe just walked through the timeline — let's run through it quickly: we'll be enrolling up to 20 patients across the U.S., Israel, and Turkey over the rest of this calendar year, meaning by the end of December. The study runs 12 weeks. After that comes data lock once the last patient is out, followed by analysis. Certain endpoints we're examining, high-resolution CT scans among them, take somewhat longer to gather than something like spirometry. We'd want all of that data available before we sit down with the agency to talk about, based on what we've seen and the access to data we plan to have if needed from the CF Foundation, from the REACH study — that's the normative dataset you've heard us mention, and they're still finishing their dataset and analysis on it right now. Most likely, that conversation with the agency would happen in the second half of next year. As for the likelihood of starting a study — we could probably have a protocol written and ready to go, but whether we could actually begin by, say, late December, I think putting a flag in the ground and saying absolutely would be speculative at this point; still, we'd certainly want to move the program forward on positive data in a population where standards of care simply aren't available. There's urgency for this patient population. I think the agency shares that feeling, and the CF Foundation, of course, is advocating strongly for rapid, stealth, thoughtful studies that can be executed efficiently and quickly. We would certainly do everything possible to try to get a study started as soon as we can. Saying end of 2027 would be a push, I think, but if it's feasible, we would certainly go for it.

Adam Walsh

analyst
#46

My second question also concerns CF. You have discussed the safety aspect somewhat and, in effect, having the open-label trial, meaning you can view the safety data. Previously you stated that any very serious adverse events would be publicly disclosed by you, and you have likewise mentioned that the complete 12 weeks have been finished by some patients. Given that every competitor program failed on safety and tolerability, that sounds fairly encouraging. It would be helpful if perhaps you could offer some thoughts and color on where things stand regarding safety. Thank you.

Joe Payne

executive
#47

Yeah, Alan, go ahead.

Alan Cohen

executive
#48

Absolutely, happy to address that. Naturally, I can't comment on anything specific. What I believe you're alluding to is Vertex's most recent quarterly earnings report, where they mentioned discontinuing advancement of their own mRNA ALN program, and my understanding is they attributed that largely to safety issues. From what we know about that study, continuing the trial required daily systemic steroids in a population already dealing with pancreatic insufficiency and blood glucose problems. On top of that, they were also administering moderate-dose inhaled long-acting bronchodilators plus inhaled corticosteroids. Luckily, our protocol hasn't required any of that; we simply use a bronchodilator, which most of these patients already take every day as standard care for airway clearance, and we only have them do so during the first two weeks. After that, if no extra pre-dosing is needed before self-administration at home, they're able to stop it. Additionally, the other programs couldn't move forward with at-home administration, and from our understanding, near the end of their program before discontinuation, they were requiring patients to come into a clinic daily for dosing, which clearly wouldn't work for an inhaled drug needing daily administration. Again, we aren't encountering those issues. At present, what I can tell you, and what I'll repeat, is that among the patient population currently enrolled, some patients have successfully completed the full 12 weeks. We've also had no severe significant safety events that would cause the Drug Safety Monitoring Committee to place stipulations on our ability to advance, ask us to halt the program, or force us to discontinue it. None of those triggers or events have occurred so far. What I can say is that enrollment in this trial continues successfully as planned, and we have interested patients around the world whom we're actively screening and enrolling, hoping to have the full data set and patient data set in by the end of calendar year. I hope that answers your question.

Adam Walsh

analyst
#49

Yes, it does. That’s quite useful, color. Thanks.

Joe Payne

executive
#50

Thank you, Adam.

Mayank Mamtani

analyst
#51

Yes, Stephen. Thanks for taking my questions, and I appreciate the detail. Sorry — one more, if I may, on 032. Could you clarify what share of patients already dosed, or those you intend to enroll through year end, are planned or have already been at the 15 mg escalated dose — or is the whole 20-patient cohort now going to receive 10 mg, so that de-escalation isn't needed?

Joe Payne

executive
#52

Yeah.

Mayank Mamtani

analyst
#53

Then-

Joe Payne

executive
#54

Yes.

Mayank Mamtani

analyst
#55

Perhaps I'll just respond to that first, and then I have something else to ask.

Joe Payne

executive
#56

Yeah, no — just to be clear on that point, our expectation is that all 20 subjects are going to be mainly class 1 CF subjects, and every one of them will have gotten 10 mg per day across the 12-week period.

Mayank Mamtani

analyst
#57

Okay, great, great, thank you. Alan, regarding what we've learned from the REACH study, if you could speak to any magnitude and consistency of the annual FEV1 or LCI data you're gaining there, is there an opportunity to use that as an external control instead of running a placebo-controlled trial in this population during phase III? I don't know how challenging that is.

Joe Payne

executive
#58

So regarding the REACH study, I'll begin there and then hand things over to Alan. We received a thorough update on REACH from the CF Foundation back in October at the NACFC, and it was encouraging to hear them report that this study has hundreds of participants across a broad age range, and that it covers several lung function measures, FEV1 and LCI, which we are collecting in the current study as well. All of that was very encouraging. Alan, I'll give the floor to you to go into more detail.

Alan Cohen

executive
#59

Yes. And beyond that, clearly the REACH study is underway and sits entirely in the hands of the people at the CF Foundation along with the academic physicians collaborating with them — they were gracious enough to sit down with us while the NACFC meeting was taking place in Atlanta in October and at least brief us on where things stand. As of now, all I can tell you is that they've done a superb job, and interest has been extremely high throughout the CF community in joining and contributing to this natural history study. As you know, the aim here was to create a natural history database that isn't available in the literature, so that sponsors such as ourselves could get hold of it and draw on it in conversations with the FDA — ideally letting us run a smaller number of patient studies and employ it as a possible natural history control, so that the placebo versus active drug arm relationship could be minimized. The patient count could be minimized too. The CF Foundation is additionally pursuing novel approaches to statistical guidance for how such studies might be carried out, given the recognition that the patient population available and willing to take part in a phase III study is genuinely fairly small. The encouraging part is that they're making progress. The data set appears as though it will be useful. It will be supportive, and we're hoping to gain access to it during the second half of next year, near the point when we'd be planning engagement with the FDA using our end of phase II data. Clearly, plenty of things must occur between now and then. At present, we keep coordinating and collaborating with the CF Foundation and the academics who run that study, so that if and when we require that information in hand to assist our negotiations and discussions with the agency regarding next steps, we'll have it in our pocket and can cite it and put it to that use. Hopefully that provides a bit more color and flavor regarding the timing, the expectations, and the hopes for what we intend to do with it, as well as other sponsors.

Mayank Mamtani

analyst
#60

That's really useful. And finally, regarding ARCT-2601, has the GLP-tox study been released internally yet, and could you share what starting dose levels you're submitting within the protocol as you prepare to file the IND? That would be helpful. Thanks very much for taking my question.

Joe Payne

executive
#61

Yes. Regarding 2601, we're getting ready to submit the IND very soon. We simply need to add the final GLP-tox studies into that report and then send it off. We've already given clear guidance that we intend to begin dosing in Q1, or next quarter, for 2601. There's nothing else we need to call out, Pad? Anything you'd like to add, or?

Pad Chivukula

executive
#62

No. Once more, on the starting dose—we haven’t disclosed that—but the dose will be one that we tested before with 810.

Mayank Mamtani

analyst
#63

Thank you, guys.

Joe Payne

executive
#64

Thanks, Mayank.

Tom Shrader

analyst
#65

Good afternoon, and thanks for all the updates. Really, about going back to 2601 dosing — I mean, 6 patients isn't a lot. Do you feel you have solid alignment with the FDA? My assumption is that you'll attempt to crosswalk to the large 810 dataset. Do you have good agreement? It sounds like your interactions have been quite positive. Do you see eye to eye on what must be demonstrated, what you need to match in order to say you understand those points? Could you give us any color on that?

Joe Payne

executive
#66

No.

Tom Shrader

analyst
#67

Great.

Joe Payne

executive
#68

Yeah. We held two Type C meetings to go over this program, and there was considerable discussion focused on LUNAR 2.0 in particular, and we worked that into this IND filing. So yes, our confidence is high, but that's exactly what the IND process exists for — to formalize it. And as soon as it's formally cleared to proceed, we'll be able to share more specifics about the protocol; as for our confidence with the small patient number, that's a luxury you get when the program you're using is potentially 38x better. And that can be determined. It isn't a case of two times better or three times better, where you'd need substantial powering for the study. It also factors in that this is simply a reformulation of ARCT-810, and so that was key in making this a relatively smooth process. But did I address your question, Tom? I wanted to make sure.

Tom Shrader

analyst
#69

Yeah, that's logical. The drop-off and everything ought to stay identical. It's the identical protein. It's just the starting level, basically.

Joe Payne

executive
#70

Yeah.

Tom Shrader

analyst
#71

Just a quick question about the vaccine. I mean, a pandemic vaccine given as a single dose is really exciting — sort of exactly what the world needs.

Joe Payne

executive
#72

Yeah.

Tom Shrader

analyst
#73

Does funding from the public sector still exist for anything with RNA in its name, or do you have any other views on that?

Joe Payne

executive
#74

Yes. So

Tom Shrader

analyst
#75

How promising is it that you might secure a BARDA grant or similar funding to advance what looks on paper like an outstanding vaccine?

Joe Payne

executive
#76

Yeah. Even though mRNA therapeutics is where we concentrate, we do recognize that non-dilutive funding tends to come with business development-style deals in the vaccine space. Pandemic preparedness contracts and deals are among the more relevant types of those arrangements. Yeah, the technology we hold is ideally suited to the next pandemic, and assisting countries in getting ready for that is an opportunity we'll keep offering to various nations moving forward. You're exactly right, self-amplifying mRNA, another instance of a single administration protecting against pandemic bird flu. That's meaningful data that came out quietly today, and hopefully it won't become relevant down the road. But it does demonstrate how broad our platform is and what self-amplifying mRNA can do, not just in infectious disease vaccines, but in oncology as well, which is a hotter topic now in the mRNA field.

Tom Shrader

analyst
#77

Yep, totally agree. Thank you.

Joe Payne

executive
#78

Thank you.

Yale Jen

analyst
#79

Good afternoon, and thank you for taking the questions. I'd like to return to the earlier question about the natural history study by CF Foundation. I realize it isn't finished yet, but at this point, with the data you've already seen, plus what you know about the current study you're still running, does putting those two together increase your confidence in the potential success of the 032 Chemic study right now? I'll follow up.

Joe Payne

executive
#80

Well, that's exactly the whole point of the REACH study — to enable sponsors. The CF Foundation is trying to help companies such as Arcturus get drugs approved for Class 1 CF. The population here is entirely untreated, and we're the first to move in this space, and they're working to support us. For exactly this reason, the CF Foundation designed the REACH study—to give us some kind of baseline control, a normative look at how Class 1 subjects progress over time, essentially a natural-history-style study. So the direct response to what you asked is yes, this stands a very good chance of benefiting us, particularly should we be lucky enough to move this forward into a phase III trial; at that point it could be drawn on to an even greater degree. Put simply, the answer is yes.

Yale Jen

analyst
#81

Alright. Perhaps just one quick follow-up, regarding the PKU program that hasn't come up much in your remarks. Might we expect to see some preclinical data at some point in the coming period, so investors can begin to get a better sense of that program too? Thanks.

Joe Payne

executive
#82

Well, as part of the — we said today that we're guiding toward an IND filing for the PKU program in the second half. Through that process, a copious amount of preclinical data gets included in the filing, and those will give us chances to share it. Maybe, Pat, would you like to offer some color?

Pad Chivukula

executive
#83

Yes. So again, during Science Day a few weeks back, I believe we showed some data regarding how we optimize RNA design. After we pick the candidate, obviously, we'll carry out a more detailed study—examining duration and examining activity. And yes, at some point we will definitely make that public too.

Joe Payne

executive
#84

There's one thing I want to add — I'm glad that question came up as we're wrapping up, since I really want to give credit to Pat and his team. It isn't only the innovations in delivery technology; it's also about extending the half-life and how long the mRNA molecule's expression lasts. Arcturus has a great deal of innovation going on, and we're quite proud of it — I only wish this call gave us more time to spotlight it. Thanks for raising that question.

Yale Jen

analyst
#85

All right, excellent. Thank you.

Joe Payne

executive
#86

Appreciate all of you joining us on this call. Please feel free to contact our team about anything still outstanding; we'll respond to you at the earliest opportunity. Many thanks once more.

Operator

operator
#87

Thanks. That takes us to the conclusion of today's meeting. We're grateful for your time and for taking part. You can go ahead and disconnect now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Arcturus Therapeutics Holdings Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Arcturus Therapeutics Holdings Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Arcturus Therapeutics Holdings Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.